ArticleNature communications2024
Senescent cancer-associated fibroblasts in pancreatic adenocarcinoma restrict CD8
Abstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed.
- Spatiotemporal transcriptomics for tumour microenvironment remodelling in cancer progression and therapy.Clinical and translational medicine · 2026Review
- Targeting cancer-associated fibroblasts: therapeutic strategies, translational challenges, and future perspectives.Journal of hematology & oncology · 2026Review
- Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer.Science (New York, N.Y.) · 2026Article
- Dual Functions of B7-H3-MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-derived Suppressor Cells and Fibroblasts.Cancer discovery · 2026Article
- Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer.Nature reviews. Gastroenterology & hepatology · 2026Review
- Molecular Mechanisms and Immune Regulation in Prostate Cancer: A Review.International journal of molecular sciences · 2026Review
- Immune surveillance and immune evasion of senescent cells.Nature reviews. Immunology · 2026Review
- Perineural Invasion, Pain and Immunosuppression Across Solid Tumours.Current oncology (Toronto, Ont.) · 2026Review
- A senescence-associated gene signature predicts radiotherapy prognosis in non-small cell lung cancer and identifies CSF1 as a target to potentiate radioimmunotherapy.Biology direct · 2026Article
- Oxidative Stress Induced Senescent Macrophage-Driven Squamous Cell Carcinoma Invasion via Glutamine Metabolic Reprogramming.Aging cell · 2026Article
- Potential of RAD51C as a hub gene and therapeutic target in bladder cancer: insights from bioinformatics and experimental analysis.International journal of surgery (London, England) · 2026Article
- Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer.Nature communications · 2026Article
- Lysine lactylation-mediated post-translational modification: Molecular mechanisms and therapeutic target exploration in tumour drug resistance.Clinical and translational medicine · 2026Review
- Trained immunity modulators: A new frontier in immunoregulation and disease intervention.Journal of advanced research · 2026Review
- Bidirectional crosstalk between cancer-associated fibroblasts and tumor immunity: shaping the microenvironment and response to immune checkpoint therapy.Experimental hematology & oncology · 2026Review
- Histology-defined activated cancer-associated fibroblasts are associated with poor survival in diffuse-type gastric adenocarcinoma.Virchows Archiv : an international journal of pathology · 2026Article
- Spatial remodeling of the tumor immune microenvironment in hepatocellular carcinoma with cirrhosis driven by Treg-CD8⁺T cell crosstalk via the SPP1-ITGA4 axis.Translational oncology · 2026Article
- Review
- Cancer-Associated Fibroblasts Functions as Multifunctional Architects of the Tumor Stroma and Represent Emerging Therapeutic Vulnerabilities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Therapy-induced senescent cancer cells as bidirectional regulators of antitumor immunity and resistance in the tumor microenvironment.Cell death & disease · 2026Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Benjamin Assouline *Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Rachel Kahn *Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Lutfi Hodali *Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Reba CondiottiDepartment of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Yarden EngelThe Lautenberg Center for Immunology and Cancer Research, Institute for Medical Research Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Ela ElyadaDepartment of Biochemistry, Institute for Medical Research Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Tzlil Mordechai-HeynDepartment of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Jason R PitarresiDivision of Hematology-Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Dikla AtiasPancreatic Cancer Translational Research Laboratory, Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0003-3362-025X
Eliana SteinbergInstitute for Drug Research, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Tirza Bidany-MizrahiThe Lautenberg Center for Immunology and Cancer Research, Institute for Medical Research Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Esther ForkoshDepartment of Gastroenterology, Hadassah Medical Center, and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Lior H KatzDepartment of Gastroenterology, Hadassah Medical Center, and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Ofra BennyInstitute for Drug Research, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.ORCID 0000-0002-2468-5978
Talia GolanPancreatic Cancer Translational Research Laboratory, Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Matan HofreeThe Lautenberg Center for Immunology and Cancer Research, Institute for Medical Research Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Sheila A StewartDepartment of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-2260-9576
Karine A AtlanDepartment of Pathology, Hadassah Medical Center, and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Gideon ZamirDepartment of Surgery, Hadassah Medical Center, and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Ben Z StangerDepartment of Medicine and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.ORCID 0000-0003-0410-4037
Michael BergerThe Lautenberg Center for Immunology and Cancer Research, Institute for Medical Research Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.ORCID 0000-0002-3469-0076
Ittai Ben-PorathDepartment of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. ittaibp@mail.huji.ac.il.ORCID 0000-0001-7815-1165
Funding
Defining metabolic adaptations within the PDAC "arid" tumor microenvironmentR01CA252225 · NCI · WISTAR INSTITUTE · PI DANG, CHI V., STANGER, BEN Z · 2021 to 2025
$2.8MStromal and vascular inputs into pancreatic cancer tumor neighborhoodsR01CA276512 · NCI · UNIVERSITY OF PENNSYLVANIA · PI M. CELESTE SIMON, BEN Z STANGER · 2023 to 2026
$2.6MMICROENVIRONMENTAL CONTROLS OF TUMOR DORMANCYR01AG059244 · NIA · WASHINGTON UNIVERSITY · PI STEWART, SHEILA A · 2018 to 2022
$2.5MSENESCENT STROMA STIMULATES INFLAMMATION TO PROMOTE TUMORIGENESISR01CA217208 · NCI · WASHINGTON UNIVERSITY · PI STEWART, SHEILA A · 2018 to 2022
$1.8MDissecting the oncogenic and pro-metastatic roles of PTHLH-mediated calcium signaling in pancreatic cancerR00CA252153 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI PITARRESI, JASON R. · 2022 to 2024
$747kIsrael Science Foundation (ISF) 2621/18NCI NIH HHS R00 CA252153NCI NIH HHS R01 CA217208NCI NIH HHS R01 CA252225NCI NIH HHS R01 CA276512NIA NIH HHS R01 AG059244
Abstract
Senescent cells within tumors and their stroma exert complex pro- and anti-tumorigenic functions. However, the identities and traits of these cells, and the potential for improving cancer therapy through their targeting, remain poorly characterized. Here, we identify a senescent subset within previously-defined cancer-associated fibroblasts (CAFs) in pancreatic ductal adenocarcinomas (PDAC) and in premalignant lesions in mice and humans. Senescent CAFs isolated from mouse and humans expressed elevated levels of immune-regulatory genes. Depletion of senescent CAFs, either genetically or using the Bcl-2 inhibitor ABT-199 (venetoclax), increased the proportion of activated CD8
Indexed as
Cancer-Associated FibroblastsCarcinoma, Pancreatic DuctalCD8-Positive T-LymphocytesCellular SenescenceImmunotherapyPancreatic NeoplasmsSulfonamidesAdenocarcinomaAnimalsBridged Bicyclo Compounds, HeterocyclicCell Line, TumorFemaleHumansImmune Checkpoint InhibitorsLymphocyte ActivationMaleBridged Bicyclo Compounds, HeterocyclicImmune Checkpoint InhibitorsSulfonamidesvenetoclax
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.